These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15383442)

  • 1. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.
    Duppenthaler A; Ammann RA; Gorgievski-Hrisoho M; Pfammatter JP; Aebi C
    Arch Dis Child; 2004 Oct; 89(10):961-5. PubMed ID: 15383442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease.
    Kristensen K; Stensballe LG; Bjerre J; Roth D; Fisker N; Kongstad T; Svendsen AL; Nielsen BW
    Arch Dis Child; 2009 Oct; 94(10):785-9. PubMed ID: 19541682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study.
    Medrano C; Garcia-Guereta L; Grueso J; Insa B; Ballesteros F; Casaldaliga J; Cuenca V; Escudero F; de la Calzada LG; Luis M; Luque M; Mendoza A; Prada F; del Mar Rodríguez M; Suarez P; Quero C; Guilera M;
    Cardiol Young; 2007 Aug; 17(4):360-71. PubMed ID: 17662160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area.
    Chiu SN; Shao PL; Chen HC; Lin MT; Huang LM; Kao FY; Huang SK; Wang JK; Wu MH
    J Pediatr; 2016 Apr; 171():25-30.e1. PubMed ID: 26822618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infection and immunoprophylaxis for selected high-risk children in Central Australia.
    Bolisetty S; Wheaton G; Chang AB
    Aust J Rural Health; 2005 Oct; 13(5):265-70. PubMed ID: 16171499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
    Boyce TG; Mellen BG; Mitchel EF; Wright PF; Griffin MR
    J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
    Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
    Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii.
    Yorita KL; Holman RC; Steiner CA; Effler PV; Miyamura J; Forbes S; Anderson LJ; Balaraman V
    Pediatr Infect Dis J; 2007 Dec; 26(12):1081-8. PubMed ID: 18043442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.